BCM
UTHR icon

Brookstone Capital Management’s United Therapeutics UTHR Stock Holding History

Brookstone Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Buy
5,944
+1,473
+33% +$830K 0.03% 399
2026
Q1 		$2.65M Sell
4,471
-2,151
-32% -$1.07M 0.03% 413
2025
Q4 		$3.23M Buy
6,622
+1,342
+25% +$625K 0.04% 370
2025
Q3 		$2.21M Buy
5,280
+349
+7% +$117K 0.03% 424
2025
Q2 		$1.42M Buy
4,931
+133
+3% +$39.7K 0.02% 488
2025
Q1 		$1.48M Buy
+4,798
New +$1.64M 0.02% 459

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Brookstone Capital Management's UTHR Position: Q2 2026 in Review

Brookstone Capital Management increased its United Therapeutics (UTHR) stake by 33% in Q2 2026, buying an estimated $830K and bringing the position to 5,944 shares worth $3.22M. The position accounts for 0.03% of the portfolio, ranked #399.

Brookstone Capital Management first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.23M in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Brookstone Capital Management held 5,944 shares of United Therapeutics worth $3.22M as of Q2 2026.
  • Brookstone Capital Management bought 1,473 United Therapeutics shares in Q2 2026, an estimated $830K.
  • United Therapeutics made up 0.03% of Brookstone Capital Management's portfolio in Q2 2026, its #399 holding.
  • Brookstone Capital Management first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Brookstone Capital Management's United Therapeutics position peaked at $3.23M in Q4 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.